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Integrin LFA-1 is a receptor that is able to transmit
multiple intracellular signals in leukocytes. Herein we
show that LFA-1 induces a potent and transient in-
crease in the activity of the small GTPase Rac-1 in T
cells. Maximal Rac-1 activity peaked 10–15 min after
LFA-1 stimulation and rapidly declined to basal levels
at longer times. We have identified Vav, a guanine
nucleotide exchange factor for Rac-1, and PI3K/Akt, as
regulators of the activation and inactivation phases of
the activity of Rac-1, respectively, in the context of
LFA-1 signaling based on the following experimental
evidence: (i) LFA-1 induced activation of Vav and
PI3K/Akt with kinetics consistent with a regulatory
role for these molecules on Rac-1, (ii) overexpression
of a constitutively active Vav mutant induces activa-
tion of Rac independently of LFA-1 stimulation
whereas overexpression of a dominant-negative Vav
mutant blocks LFA-1-mediated Rac activation, (iii)
pharmacological inhibition of PI3K/Akt prevented the
fall in the activity of Rac-1 after its initial activation
but had no effect on Vav activity, and (iv) overexpres-
sion of a dominant-negative or a constitutively active
Akt-1 induced or inhibited, respectively, Rac-1 activ-
ity. Finally, we show that T cells with a sustained Rac
activity have impaired capacity to elongate onto
ICAM-1. These results demonstrate that down-regula-
tion of the activity of this GTPase is a requirement for
the regulation of T cell morphology and motility and
highlight the importance of temporal regulation of the
signaling triggered from this integrin.
T lymphocytes are primarily circulating cells in the vascular
system until they sense signals that trigger their adhesion to
endothelial cells and their migration across the endothelial
monolayer into the subendothelial tissue. Acquisition of a po-
larized phenotype by T lymphocytes is an essential feature that
is required for crucial functions performed by these cells, in-
cluding extravasation, oriented migration toward inflamma-
tory sites, and interaction with antigen presenting cells during
antigen recognition (1–3).
The integrin LFA-1 (lymphocyte function-associated anti-
gen-1, also known as CD11a/CD18 or L2) is a member of the
leukocyte (2) subfamily of integrins that is expressed on the
cell surface of all leukocytes (4, 5). This molecule mediates
important adhesive phenomena through interactions with its
ligands intercellular adhesion molecules (ICAM-1,1 -2, or -3).
Resting T lymphocytes express an inactive form of the integrin
LFA-1 with low affinity/avidity for its ligands. However, leu-
kocyte activation through different cell surface receptors, in-
cluding the T cell receptorCD3 complex and receptors for cy-
tokines and chemokines, results in activation of LFA-1
molecules (6–8). Activation of LFA-1 molecules can also be
induced from outside the cells by different protocols, including
(i) induction of integrin clustering following cross-linking with
a secondary antibody, (ii) altering the extracellular divalent
cation conditions, i.e. by addition of micromolar concentrations
of Mn2 (9), or (iii) addition of specific activating or stimulatory
mAbs (such as the CD18-specific mAb KIM-127 (10, 11) that,
upon binding to the  or the  subunits of LFA-1, alter the
conformation of the integrin to a state of increased affinity for
its ligands.
Integrins are currently recognized to work not merely as
adhesion molecules but as cell surface receptors capable of
efficiently transducing a variety of signals to the cell interior.
For integrin LFA-1 in particular, the intracellular signals that
are generated in T cells following ligand engagement of this
receptor have not been fully characterized. It has been de-
scribed that LFA-1 signaling includes phosphorylation of phos-
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pholipase C1, phospholipid hydrolysis, activation of different
isoenzymes of protein kinase C, mobilization of intracellular
Ca2, and activation of tyrosine kinases (12–18). We have
reported recently that activation of integrin LFA-1 on T lym-
phocytes and subsequent cell adhesion onto immobilized ligand
ICAM-1 leads to a T cell phenotype characterized by strong
adhesion, acquisition of an elongated morphology, cessation of
cell motility, and activation of the intracellular tyrosine kinase
PYK-2 (17–19). These events become apparent 30–40 min after
activation of LFA-1 and adhesion of cells and were completely
dependent on the reorganization of actin cytoskeleton, because
they were completely blocked by cytochalasin D (17).
Phosphoinositide 3-kinases (PI3Ks) are a family of intracel-
lular signal transducing enzymes that share the capacity to
phosphorylate phosphatidylinositol lipids at the D-3 position of
the inositol ring. Three classes of PI3Ks have been defined
based on their structure and subunit composition, substrate
specificity, and regulatory mechanisms. Class I PI3Ks are the
best characterized in leukocytes. The lipid products of class I
PI3Ks are involved in the coordination of a set of events leading
to cell growth, cell cycle entry, cell migration, and cell survival,
through the targeting of numerous cytosolic proteins that con-
tain domains that specifically bind to D-3 phosphorylated phos-
phoinositides. The fungal metabolite wortmannin and the
pharmacological compound LY294002 are two potent inhibitors
of class I PI3Ks that have been used extensively to study the
physiological role of class I PI3Ks in various cellular responses.
Through the use of these inhibitors, class I PI3Ks have been
shown to play an important role in the control of chemotactic
peptide- and chemokine-induced polarization and cytoskeletal
organization in leukocytes (20, 21). The serine-threonine ki-
nase Akt-1 is a major target of PI3K that plays a role in
protecting many cell types from apoptosis and in promoting cell
survival (22, 23). Recently, the PI3K/Akt-1 pathway has also
been involved in the control of neutrophil chemotaxis (24).
Akt-1 is activated by phosphorylation by the kinase PDK-1,
following binding through its pleckstrin homology domain to
the PI3K lipid products on the plasma membrane.
Members of the Rho subfamily of small GTPases, including
Rho, Rac, and Cdc42, play crucial roles in the regulation of
cytoskeletal organization in many cell types, including leuko-
cytes (25–29). The Rho family member Rac-1 has been shown to
be essential for cytoskeletal changes and spreading, polariza-
tion and chemotaxis of different leukocyte populations on fi-
bronectin and other ligands for 1 integrins (30–33). These
proteins cycle between a GDP-bound state (inactive) and a
GTP-bound (active) state that is able to interact and activate
their downstream signaling effectors. The intrinsic GTPase
activity of Rho family GTPases is potentiated by GTPase-acti-
vating proteins that therefore favor the inactive state (GDP-
bound) of these GTPases whereas guanine nucleotide exchange
factors (GEFs) induce the release of GDP and binding of new
GTP. Vav is 95-kDa multidomain protein that works as a key
GEF for Rac GTPases in hematopoietic cells. In T lymphocytes
Vav is involved in the T cell receptor signaling that leads to
activation of Rac-1 and cytoskeletal rearrangements (34). Vav
guanine exchange activity is primarily regulated through phos-
phorylation by different intracellular tyrosine kinases of the
Src and Syk families although binding of Vav through its
pleckstrin homology domain to phosphoinositide products of
PI3K may represent an additional level of regulation of the
activity of this GEF (35–37). In this paper, we show that fol-
lowing LFA-1 activation and ligand engagement in T lympho-
cytes the Rho family member Rac-1 is transiently activated.
Furthermore, we demonstrate that LFA-1 induces activation of
Vav and PI3K/Akt, which in turn regulate the activation and
inactivation of Rac-1, respectively. By transfecting T cells with
constitutively active mutant forms of Vav and Rac-1 and
through pharmacological inhibition of PI3K/Akt-1 we show
that the inactivation of Rac-1 is necessary for the processes of
T cell polarization and motility mediated by LFA-1.
MATERIALS AND METHODS
Cell Culture—Human T lymphoblasts were prepared from periph-
eral blood mononuclear cells by treatment with 10 g/ml phytohemag-
glutinin (Amersham Biosciences) for 48 h as described previously (9).
Cells were washed and cultured in RPMI 1640 (BioWhittaker) contain-
ing 10% fetal calf serum (Harlam Sera-Lab.) 50 units/ml penicillin, 50
mg/ml streptomycin (P/E; BioWhittaker), 2 mM L-glutamine (L-Gln;
BioWhittaker), and 50 units/ml interleukin-2 (Eurocetus). T lympho-
blasts cultured by 10–12 days were typically used in all experiments.
The human T cell line HSB-2 was cultured in RPMI 1640, 10% fetal calf
serum, 50 units/ml penicillin/2 mM L-glutamine, and 50 mg/ml
streptomycin.
Antibodies and Reagents—ICAM-1-Fc chimeric protein consisting of
the five domains of ICAM-1 fused to the Fc fragment of human IgG1
was prepared as described (38). The anti-CD18 mAb Lia3/2.1 (39) was
purified from mouse ascites by protein A affinity chromatography. The
monoclonal antibody KIM-127 was obtained from Dr. Martin Robinson
(Celltech Group, Berkshire, United Kingdom) (40). Anti-p85 PI3K poly-
clonal antibody was from Upstate Biotechnology (Lake Placid, NY). The
anti-phospho-Akt-Ser473 and anti-Akt-1 polyclonal antibodies were
from Pharmingen. The monoclonal antibodies anti-Rac-1, anti-PY20,
and polyclonal anti-Vav1 were from Transduction Laboratories. Anti-
PYK-2 (C-19) polyclonal antibody was from Santa Cruz. The polyclonal
anti-phospho-Tyr174-Vav antibody, which specifically detects active
Vav, has been described previously (41). The antibody that recognizes
the consensus sequence RLRPLpS/pT that is phosphorylated by Akt-1
was purchased from Cell Signaling (Beverly, MA). The polyclonal anti-
phospho-Ser antibody was from Zymed Laboratories Inc. (San Fran-
cisco, CA). The monoclonal anti-AU5 and anti-AU1 antibodies were
from Covance (Berkeley, CA). [-32P]ATP (6000 Ci/mmol) were from
American Radiolabeled Chemicals. BSA, poly-lysine, LY294002, L--
phosphatidylinositol, protein A-agarose, protein G-agarose, glutathi-
one-agarose, polyclonal anti-mouse-IgG, and secondary peroxidase-con-
jugated antibodies were from Sigma. Wortmannin, geneticin, and
isopropyl-1-thio--D-galactopyranoside were from Calbiochem. Oxyl-
ated silica gel plates were from Merck. The enhanced chemiluminescent
solution (ECL) was from Amersham Biosciences.
Expression Constructs and Transient Transfection Assays—The
pEGFP-C1 expression vector obtained from Clontech (Palo Alto, CA),
the dominant-negative Rac (DN-Rac) pEGFP-C1-N17Rac expression
plasmid, and the constitutively active Rac cDNA (CA-Rac) pEGFP-C1-
V12Rac expression plasmid have been described previously (31). The
pcDNA3-AU1BAD and pCEFL-AU5Rac-1, termed Rac-1-AU5 and
BAD-AU1, respectively, were described previously (42, 43). Kinase-
dead EGFP-Akt-1 (K179M), which acts as a dominant-negative (DN-
Akt-1), and myr-EGFPAkt-1, which acts as a constitutively active mu-
tant (CA-Akt-1) of Akt-1, respectively, have been described elsewhere
(44, 45). The CA-Vav construct pEGFP-C2-Vav-(1–186) and the DN-
Vav construct that only contains the SH3-SH2-SH3 domains of Vav
(pEGFP-C2-SH3-SH2-SH3-Vav) have been described previously (37).
For transient transfection experiments, HSB-2 cells (3.5  107) were
washed twice with cold RPMI and resuspended in 500 l of cold Opti-
MEM (Invitrogen) before being placed in a 0.4-cm electroporation cu-
vette (BTX Instruments, Holliston, MA). DNA (15 g) was added, and
transfections were conducted at 310V 2 pulses for 10 ms using a
ECM830 BTX electroporation system. After the electroporation bursts,
the cells were transferred to plastic dishes and cultured in RPMI 1640
containing 10% fetal calf serum and 2 mM L-glutamine. Transfection
efficiencies were estimated by flow cytometry 16–24 h after
electroporation.
Cell Attachment and Morphological Analysis of T Cells—Induction of
T cell adhesion to either ICAM-1 or poly-L-lysine-coated dishes was
performed as described elsewhere (17). Briefly, 96-well flat-bottom
plates and 35- and 90-mm dishes were pre-coated overnight at 4 °C with
5 g/ml ICAM-1-Fc in PBS, blocked with 1% BSA in PBS for 1 h at room
temperature, and then washed twice with RPMI 1640. In control inte-
grin-independent adhesion experiments, wells or dishes were pre-
coated overnight at 4 °C with 20 g/ml poly-L-lysine in PBS. T cells were
washed twice with RPMI 1640 and starved in RPMI 1640 without
serum for 90 min. In some cases cells were pre-treated for 30 min at
37 °C with the PI3K inhibitors (100 M LY294002 or 100 nM wortman-
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nin). After this pre-incubation, cells were plated on the dishes and
stimulated or not by the addition of 200 M Mn2 or 10 g/ml KIM-127
mAb to activate LFA-1. Cells were then incubated at 37 °C for different
periods of time prior to lysis and further analysis of Rac-1, Vav, PI3K,
Akt-1, or PYK-2. For morphological studies, T cells were allowed to
adhere for 90 min and then unbound cells were removed by three
washes with PBS. Attached cells were fixed in 3% formaldehyde in PBS
for 10 min at room temperature, permeabilized in 2% methanol in PBS
for 5 min at room temperature, and stained with 0.5% crystal violet in
20% methanol. The morphological changes were analyzed by
microscopy.
LFA-1 Cross-linking Activation—T cells (5–20  106 cells for each
condition) were washed twice and starved in RPMI 1640 with 20 mM
Hepes (RPMI-Hepes) for 90 min. Cells were then pre-treated or not for
30 min at 37 °C with the PI3K inhibitors (100 M LY294002 or 100 nM
wortmannin). After this period, cells were treated with the anti-LFA-1
mAb Lia3/2.1 (10 g/ml) and incubated with gentle rotation for an
additional period of 50 min at 4 °C. Unbound antibody was removed by
subjecting the cells to three washes in 20 mM Hepes/RPMI medium.
LFA-1 was cross-linked by adding polyclonal anti-mouse-IgG (25 g/ml)
in 20 mM Hepes/RPMI medium. Finally, cells were washed once with
cold 20 mM Hepes/RPMI medium and lysed in the appropriate buffer
(see “Immunoprecipitation and Western Blotting”).
Immunoprecipitation and Western Blotting—For PI3K immunopre-
cipitation, cells were lysed in Buffer A (20 mM Tris, pH 7.4, 1% Triton
X-100, 40 mM NaCl, 1 mM Na3VO4, 1 mM PMSF, 10 g/ml leupeptin, 5
g/ml aprotinin, 10 g/ml pepstatin, 10% glycerol). To study Akt-1
phosphorylation cells were lysed in Buffer B (20 mM Tris-HCl, pH 7.5,
1% Nonidet P-40, 137 mM NaCl, 20 mM NaF, 1 mM NaPPi, 1 mM
Na3VO4, 10 g/ml leupeptin, 5 g/ml aprotinin, 10 g/ml pepstatin, 1
mM PMSF, 10% glycerol). For Vav analysis cells were lysed in Buffer C
(25 mM Tris-HCl, pH 7.8, 1% Triton X-100, 1 mM EDTA, 20 mM NaF, 1
mM Na3VO4, 1 mM NaPPi, 10 g/ml leupeptin, 5 g/ml aprotinin, 10
g/ml pepstatin, 1 mM PMSF, 10% glycerol). Cells used to study PYK-2
were lysed in Buffer D (10 mM Tris, pH 7.6, 5 mM EDTA, 50 mM NaCl,
30 mM NaPPi, 50 mM NaF, 2.1 mM Na3VO4, 1% Triton X-100, 50 g/ml
leupeptin, 50 g/ml aprotinin, 5 g/ml pepstatin, 1 mM PMSF). In Rac
phosphorylation studies, cells were lysed in Buffer E (50 mM Tris-HCl,
pH 7.4, 1% Nonidet P-40, 137 mM NaCl, 10% glycerol, 5 mM MgCl2, 20
mM NaF, 1 mM NaPPi, 1 mM Na3VO4, 10 g/ml leupeptin, 5 g/ml
aprotinin, 10 g/ml pepstatin, 1 mM PMSF). All lysates were clarified by
centrifugation at 14,000 rpm for 15 min, and the pellets were discarded.
For PI3K, Vav, Rac phosphorylation, and PYK-2 assays, immune com-
plexes from supernatants were precipitated overnight at 4 °C with
protein A or protein G linked to agarose. Immunoprecipitates were
washed three times with the specific lysis buffer and either used for
PYK2/PI3K in vitro kinase reactions or extracted in 2 SDS-PAGE
sample buffer (200 mM Tris-HCl, pH 6.8, 0,1 mM Na3VO4, 1 mM EDTA,
6% SDS, 4% 2-mercaptoethanol, and 10% glycerol) and boiled for 5 min
for one-dimensional SDS-PAGE. To analyze Akt activation, clarified
lysates were extracted in 5 SDS-PAGE sample buffer whereas to
study Rac phosphorylation Rac-AU5 from clarified lysates was immu-
noprecipitated and then extracted in 2 SDS-PAGE sample buffer.
After SDS-PAGE, proteins were transferred to nitrocellulose or polyvi-
nylidene difluoride membranes. Membranes were blocked using 3%
nonfat dried milk or 3% BSA in PBS and incubated with the appropri-
ate antibodies. Immunoreactive bands were visualized using enhanced
chemiluminescence reagents.
PI3K in Vitro Kinase Reactions—Reactions were performed as de-
scribed (46). Briefly, immunoprecipitates were washed and pelleted three
times in Lysis Buffer A (see “Immunoprecipitation and Western Blotting”)
and twice with kinase buffer (20 mM Tris-HCl, 7.5 mM NaCl, 20 mM
Hepes, 10 mM MgCl2, 200 mM adenosine). Pellets were dissolved in 50 l
of kinase buffer, and the reaction was started by adding 5 Ci of
[-32P]ATP and 20 g of L--phosphatidylinositol. The mixture was incu-
bated at room temperature for 15 min, and the reaction was stopped by
adding 100 l of chloroform. Lipids were extracted by adding 200 l of
chloroform:methanol:HCl (100:200:2, v/v). After centrifugation at 3,000
rpm at 4 °C, 50 l of the lower organic phase was applied to an oxylated
silica gel plate. Lipids were resolved by thin-layer chromatography using
a solvent mixture of cloroform:methanol:water (75:20:5, v/v). Phosphati-
dylinositol 3-phosphate was detected by autoradiography.
PYK-2 in Vitro Kinase Reactions—Reactions were performed as de-
scribed (17, 19). Briefly, immunoprecipitates were washed and pelleted
three times in Lysis Buffer D and twice with kinase buffer (20 mM
Hepes and 3 mM MnCl2, pH 7.35). Pellets were dissolved in 40 l of
kinase buffer, and the reactions were started by adding 10 Ci of
[-32P]ATP. Reactions were carried out at 30 °C for 15 min and then
stopped on ice by adding 10 mM EDTA. Pellets were washed in lysis
buffer containing 10 mM EDTA, extracted for 5 min at 90 °C in 2
SDS-PAGE sample buffer, and analyzed by SDS-PAGE and
autoradiography.
Rac-1 Pull-down Activity Assays—GST-PAK-CRIB fusion proteins
were a kind gift from Dr. J. G. Collard (The Netherlands Cancer Insti-
tute, Amsterdam, The Netherlands). Rac activity assays were per-
formed with slight modifications as described previously by Sander et
al. (47). In brief, after induction of LFA-1 activation (by Mn2- or
KIM-127-induced adhesion to ICAM-1 or cross-linking) and/or transfec-
tion with relevant constructs, T cells were lysed in 500 l of ice-cold
Lysis Buffer E (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 137 mM
NaCl, 10% glycerol, 5 mM MgCl2, 20 mM NaF, 1 mM NaPPi, 1 mM
Na3VO4, 10 g/ml leupeptin, 5 g/ml aprotinin, 10 g/ml pepstatin, 1
mM PMSF). Lysates were cleared by centrifugation, and 15 l of these
samples were used for loading controls. Cleared lysates were incubated
overnight at 4 °C with GST-PAK-CRIB coupled to glutathione-agarose
beads to precipitate GTP-bound Rac-1. Precipitated complexes were
washed three times in ice-cold Lysis Buffer E and boiled in sample
buffer (100 mM Tris-HCl, pH 6.8, 0,05 mM sodium orthovanadate, 0.5
mM EDTA, 3% SDS, 2% 2-mercaptoethanol, and 5% glycerol). Proteins
from total lysates and precipitates were fractionated by 15% SDS-
PAGE, transferred to polyvinylidene difluoride membranes, and immu-
noblotted with anti-Rac-1 mAb.
Time-lapse Fluorescence Microscopy—HSB-2 T cells were transiently
transfected with CA-Vav cDNA or CA-Rac cDNA (see “Expression Con-
structs and Transient Transfection Assays”) as described above and
grown in complete RPMI 1640 medium for 16–24 h. Then, after removal
of death cells by a Ficoll gradient, cells were starved for 90 min,
resuspended in 1 ml of 20 mM Hepes-RPMI 1640 medium, and plated
onto 35-mm dishes that had been coated previously with 2.5 g/ml
ICAM-1-Fc overnight at 4 °C and saturated with 1% heat-denatured
BSA for 2 h at room temperature. LFA-1 on T cells was activated with
mAb KIM-127 (10 g/ml) or with MnCl2 (200 M), and cells were
recorded for a period of 90 min. Fluorescence and phase contrast images
were acquired at 20-s intervals with a 40 objective on a Leica DM-
IRE2 microscope equipped with digital camera and Q-fluoro time-lapse
Leica Software.
RESULTS
LFA-1 Induces Transient Activation of the Small GTPase
Rac-1—Because the Rho family member Rac-1 GTPase is a
major regulator of the organization of the actin cytoskeleton in
most cell types including T lymphocytes (31, 48), we decided to
explore in more detail whether the activity levels of this small
GTPase in T cells are altered following LFA-1 activation and
ligand engagement. Pull-down assays using the fusion protein
GST-PAK-CRIB, a Rac-1 binding domain of the PAK effector
molecule that only binds the active GTP-bound-Rac-1, and
glutathione-agarose were performed to detect changes in the
activity of Rac-1 in T lymphoblasts at various time periods after
induction of LFA-1 activation. Three different protocols to in-
duce LFA-1 activation and signaling were used: (i) addition of
200 M divalent cation Mn2 to the extracellular medium and
adhesion onto ligand ICAM-1 (Fig. 1A), (ii) use of the stimula-
tory anti-CD18 mAb KIM-127 and adhesion onto ICAM-1 (Fig.
1B), and (iii) induction of clustering of the LFA-1 molecules by
cross-linking with the specific anti-CD18 mAb Lia3/2.1 (Fig.
1C). Interestingly, as shown in Fig. 1, a transient increase in
the activity of Rac-1 is consistently observed following the
induction of LFA-1 activation and signaling regardless of the
method employed. Maximal levels of Rac-1 activation (almost
6-fold) were detected 10–15 min after LFA-1 activation and
then declined to basal levels at longer times (30 min). Identical
transient kinetics of Rac-1 activity was observed when the
activation of integrin LFA-1 was induced on the HSB-2 T cell
line (not shown), indicating that this phenomenon is not re-
stricted to a particular T cell type.
LFA-1 Mediates Rac Activation through the GEF Vav—The
transient nature of Rac-1 activation following LFA-1 stimula-
tion suggests that distinct upstream signaling components
might be responsible for the initial increase in Rac-1 activity
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(activation phase) and for the subsequent return to basal ac-
tivity (inactivation phase) observed at longer times. Vav is a
GEF that has been demonstrated to increase the activity of
Rac-1 in several hematopoietic cell types (34). Moreover, tyro-
sine phosphorylation of Vav has been shown to mediate acti-
vation of p21Ras following 2 integrin triggering in neutrophils
(49). Thus, it was of interest to determine whether activation of
Vav could account for the initial increase in Rac-1 activity
following LFA-1 stimulation in T lymphocytes. For this pur-
pose, cross-linking of the anti-LFA-1 mAb Lia3/2.1 was used to
induce signaling from this integrin in HSB-2 T cells. Fig. 2A
shows that Vav was rapidly and transiently phosphorylated
following antibody-induced clustering of LFA-1 in HSB-2 T
cells. The maximal phosphorylation of Vav was observed 2–5
min after ligation of the integrin, returning to basal levels at
longer times. As tyrosine phosphorylation can result in both
activation and down-modulation of the activity of Vav (41, 50),
we have also analyzed more specifically the LFA-1-mediated
activation of Vav by Western blot using a specific antibody that
recognizes active Vav (phospho-Tyr174) (41, 50). As shown in
Fig. 2B, LFA-1 stimulation induces the activation of Vav at 2
min. Pretreatment of cells with the PI3K inhibitor LY294002
did not affect the activation of Vav. This rapid kinetics of Vav
activation and subsequent return to basal activity was compat-
ible with its function as a GEF responsible for the initial
activation Rac-1. Further support for the role of Vav as a key
GEF for Rac-1 in T lymphocytes was obtained by transiently
transfecting HSB-2 cells with constitutively active and domi-
nant-negative forms of Vav (CA-Vav and DN-Vav). Fig. 2C
shows that in HSB2 cells transfected with CA-Vav the basal
levels of GTP-Rac-1 (in the absence of LFA-1 stimulation) were
enhanced compared with cells transfected with control pEGFP
plasmid. Interestingly DN-Vav reduced Rac-1 activity below
basal levels, and LFA-1 cross-linking could not activated Rac.
Altogether, these results suggest the important role of this
GEF in the regulation of Rac-1 activity in T cells following
LFA-1 engagement.
LFA-1 Induces Transient Activation of PI3K—Several re-
ports have demonstrated a central role for PI3K in integrin-
mediated cellular responses in a variety of cells, including
different types of leukocytes (22). We decided to study whether
PI3K was also implicated in the observed LFA-1-driven activa-
tion of Rac-1 in T cells. We first analyzed the changes in
activity of this intracellular enzyme at different times after the
induction of activation of LFA-1. For this purpose, T lympho-
blasts were plated on dishes coated with ligand ICAM-1 and
treated for different time periods with Mn2 to induce the
activation of LFA-1. After these treatments T cells were lysed,
PI3K was immunoprecipitated, and the resulting immunocom-
plexes incubated with [-32P]ATP (see “Materials and Meth-
ods”). The phosphorylating activity of PI3K toward its sub-
strate L--phosphatidylinositol was analyzed by thin-layer
chromatography and autoradiography. As shown in Fig. 3A,
the activity of PI3K was increased following the Mn2-induced
activation of LFA-1 and subsequent cell adhesion onto ligand
ICAM-1. Maximal activity was observed after 5 min (14-fold)
and then decreased to almost basal levels after 30 min of LFA-1
activation. This increase in PI3K activity was dependent on the
activation of LFA-1 as demonstrated by the fact that no en-
hanced activity was observed after 10 min of LFA-1-mediated T
FIG. 1. LFA-1 induces transient activation of Rac-1 in T cells. Rac-1 activity was analyzed in T lymphoblasts. LFA-1 was activated for
different time periods, cells were lysed, and Rac-1 activated fraction (Rac-1-GTP) was pulled down using GST-PAK-CRIB-agarose beads. Aliquots
from lysates were also used to analyze the total levels of Rac-1 by Western blotting using an anti-Rac-1 mAb. Three different protocols were used
to induce activation of LFA-1. A, T lymphocytes were allowed to adhere onto ICAM-1 or poly-L-lysine-coated dishes, and LFA-1 was stimulated ()
or not () with 200 M MnCl2. -Fold activation of Rac-1 over basal levels was quantified, and the kinetics of activation is represented. B, LFA-1
was activated with the stimulatory anti-CD18-specific mAb KIM-127. Cells were then allowed to adhere onto ICAM-1-coated dishes for the times
indicated before lysis and pull-down assays. The upper band that appears in some of the Rac-1 loading controls corresponds to the KIM-127
antibody light chain. C, LFA-1 was directly clustered by cross-linking (XL-Lia3/2.1) of the anti-CD18 mAb Lia3/2.1 with a secondary antibody.
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FIG. 2. LFA-1 activates Rac through a Vav-dependent pathway. A, HSB-2 T cells suspended in RPMI plus 20 mM Hepes were incubated
with anti-LFA-1 mAb Lia3/2.1 (10 g/ml), and cross-linking of this antibody was induced as explained under “Materials and Methods” for different
time periods. Cells were lysed, and Vav proteins from lysates were immunoprecipitated with anti-Vav antibody and immunoblotted with
anti-phosphotyrosine (PY20) mAb (upper panel). Aliquots of total lysates were analyzed by Western blot (WB) with anti-Vav antibody to show equal
loading (lower panel). -Fold activation of Vav over basal levels was quantified, and the kinetics of activation is represented. B, Vav activation was
induced by cross-linking LFA-1 in HSB-2 T cells pretreated (LY294002) or not () with the PI3K inhibitor LY294002 at 100 M and then cells
were lysed in Buffer D, and Vav was immunoprecipitated (IP) (see “Materials and Methods”). Vav activation was detected by Western blot with
the anti-phospho-Tyr174-Vav antibody. Control load of total Vav is also shown. The level of activation of Vav was quantified and represented. C,
transfected HSB-2 T cells with pEGFP, CA-Vav, and DN-Vav were used to perform pull-down assays as specified under “Materials and Methods.”
Upper panel, active Rac-1 (GTP-Rac-1) was detected by Western blot using the anti-Rac-1 antibody. Lower panel, total Rac-1 levels were analyzed
by immunoblotting using aliquots of total lysates. Values of bars in B and C represent -fold activation with respect to basal levels.
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lymphocyte adhesion onto ligand ICAM-1 in the absence of
Mn2 (Fig. 3B) or following cell adhesion onto a nonspecific
ligand poly-L-lysine (not shown). Similar results were obtained
when activation of LFA-1 and adhesion of T lymphoblasts to
ligand ICAM-1 was induced with mAb KIM-127 or when inte-
grin LFA-1 was cross-linked with the specific anti-CD18 Lia3/
2.1 mAb (not shown). Identical kinetics of PI3K activation was
obtained with the human T cell line HSB-2 (not shown). Pre-
treatment of T lymphoblasts with the PI3K-specific inhibitors
wortmannin (100 nM for 30 min) or LY294002 (100 M for 30
min) completely abrogated the induction of activation of this
lipid kinase after integrin LFA-1 engagement (Fig. 3B), con-
firming the specific detection of PI3K activity in these assays.
LFA-1 Induces Activation of Akt-1—As the kinase Akt-1 is a
major PI3K effector (22, 23), we investigated its possible impli-
cation in the signaling pathway triggered by LFA-1. We ana-
lyzed the levels of the phosphorylated Akt-1 (active Akt-1 phos-
phorylated at Ser-473) by Western blot from lysates of T
lymphoblasts treated with Mn2 and allowed to adhere onto
ICAM-1-coated dishes for various time periods. As shown in
Fig. 4A, an increase in Akt-1 phosphorylation was evident 10
min after Mn2-induced LFA-1-activation, remaining still high
after 60 min. This activation of Akt-1 was completely depend-
ent on PI3K, because it was abrogated by preincubating the
cells with the PI3K inhibitor LY294002 (Fig. 4B), confirming
the upstream position of PI3K relative to Akt-1 in this signal-
ing pathway. When the interaction of LFA-1 integrin with its
ligand ICAM-1 was prevented by using the blocking anti-LFA-1
mAb Lia3/2.1 no activation of Akt-1 was observed, clearly dem-
onstrating its dependence on LFA-1 (Fig. 4B). A similar kinet-
ics of activation of Akt-1 following cross-linking of LFA-1 was
observed with the T cell line HSB-2 (see Fig. 5).
The PI3K/Akt-1 Axis Is a Negative Regulator of LFA-1-medi-
ated Rac-1 Activity—To demonstrate the involvement of the
PI3K/Akt-1 axis in the control of Rac-1 activity following LFA-1
engagement, T cells were pretreated with the PI3K inhibitor
LY294002, and the activity levels of Rac-1 were analyzed at
different times after cross-linking of LFA-1. Interestingly, un-
der these conditions of inhibition of PI3K the activation of
Rac-1 was no longer transient, but it was converted into a more
stable activation kinetics. As shown in Fig. 5 (upper panel), in
T cells treated with LY294002 the Rac-1 activation phase was
similar, and maximal levels of GTP-Rac-1 were also observed
10 min after LFA-1 activation as in control untreated cells.
However, the subsequent return to basal levels of Rac-1 activ-
ity that was observed at longer times in control cells was
prevented. Under the same conditions, LY294002 caused a
blockade of Akt-1 activation (Fig. 5, lower panel), demonstrat-
ing that the PI3K/Akt-1 was inhibited by this compound. These
results indicate that PI3K behaves as an inhibitory molecule
acting upstream of Rac-1 in the LFA-1 signaling pathway. To
directly test the involvement of Akt-1 in the control by PI3K of
Rac-1 activity, we transiently transfected the HSB-2 T cell line
with cDNA constructs coding for constitutively active or dom-
inant-negative forms of Akt-1 (CA-Akt-1 and DN-Akt-1; both
fused to EGFP). Fig. 6A shows that transfection of HSB-2 T
cells with CA-Akt-1 resulted in lower levels of active Rac-1
compared with cells transfected with DNA control plasmid
(pEGFP), whereas the levels of active Rac-1 (GTP-Rac-1) were
elevated in HSB-2 T cells transfected with DN-Akt-1. These
results demonstrate that in T cells Akt-1 exerts an inhibitory
effect on the activity of Rac-1. Accordingly, it has been reported
(51) that in vitro Akt-mediated phosphorylation of Ser74-Rac
leads to its inactivation. To test this point with intact cells, we
have examined Rac phosphorylation in HSB-2 T cells trans-
fected with CA-Akt-1. Using two different antibodies, a general
anti-phospho-serine antibody (not shown) and also a specific
antibody that detects the consensus sequence (RLRPLpS/pT)
that is phosphorylated specifically by Akt-1, we have not de-
tected an increase in Rac phosphorylation (Fig. 6B). As a con-
trol we used Bad, a well established substrate of Akt-1, which
was readily phosphorylated by CA-Akt-1 (not shown). Taken
together, the data indicate that PI3K/Akt-1 is responsible for
the decline and return to basal levels of activity of the Rac-1
GTPase observed at 20 min after induction of LFA-1 activation
by a mechanism that in vivo does not seem to involve a direct
Akt-1 phosphorylation of Rac (see Figs. 5, 6, and 8).
Transient Activation of Rac-1 Is Required for T Cell Polar-
ization and Migration on ICAM-1—The results presented
above demonstrate that activation of LFA-1 on T cells triggers
two signaling pathways involving Vav and PI3K/Akt-1 that
control the activity of Rac-1. To directly confirm that Rac-1
activity plays an essential role in the control of T cell morphol-
ogy and motility, we obtained HSB-2 T cells with sustained
enhanced Rac-1 activity by overexpressing either CA-Vav or
CA-Rac-1 constructs. Transfected cells were plated on ICAM-1,
FIG. 3. LFA-1 induces transient ac-
tivation of PI3K. T lymphoblasts were
allowed to adhere onto ICAM-1-coated
dishes. A, upper panel, cells were stimu-
lated with 200 M Mn2 for the indicated
times and then lysed, PI3K was immuno-
precipitated with a p85-specific antibody,
and kinase activity was measured as de-
scribed under “Materials and Methods.”
Lower panel, total PI3K levels were ana-
lyzed by immunoblotting using anti-p85
antibody. B, upper panels, T cells were
pretreated for 30 min with PI3K inhibi-
tors LY294002 (100 M) or wortmannin
(100 nM) before being stimulated or not
with 200 M Mn2 for 10 min. Lower
panel, total PI3K levels were analyzed by
immunoblotting as in A. The quantifica-
tion of the PI3K activity is represented in
the bar graphs in A and B.
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and LFA-1 was activated with the stimulatory antibody KIM-
127 (or with Mn2; not shown). As shown in Fig. 7A the mor-
phological elongation (and also the motility; not shown) of T
cells was completely blocked in these transfected HSB-2 cells,
whereas in cells transfected with control vector pEGFP no such
inhibition was observed (not shown). In addition, as the inhi-
bition of the PI3K/Akt-1 signaling pathway with LY294002
blocks the inactivation phase and results in sustained activa-
tion of Rac-1 (see Figs. 5 and 6) we expected that this inhibition
of PI3K should also result in inhibition of T cell polarization. As
shown in Fig. 7B, treatment of T lymphoblasts (or HSB-2 T
cells; data not shown) with the PI3K inhibitors LY294002 (or
wortmannin; not shown) prior to the induction of activation of
integrin LFA-1 (either with Mn2 or with the specific stimula-
tory anti-CD18 mAb KIM-127) completely abrogated the acqui-
sition of the elongated polarized T cell morphology on ICAM-1.
As we have demonstrated before, LFA-1 induces activation of
the tyrosine kinase PYK-2 in T cells (17–19), and this activa-
tion was completely dependent on changes in T cell morphol-
ogy; therefore we also expected that inhibition of changes in
morphology because of PI3K inhibition and concomitant Rac-1
sustained activation would also block LFA-1-dependent activa-
tion of PYK-2. As shown in Fig. 7C, treatment of the cells with
the PI3K inhibitor abrogated the activation of PYK-2. Taken
together, these results demonstrate that inactivation of Rac-1
is required for LFA-1-dependent cell polarization and motility
in T cells.
DISCUSSION
The leukocyte integrin LFA-1 mediates the adhesive inter-
actions of T lymphocytes with endothelial cells during che-
mokine-directed extravasation into inflammatory foci and
with antigen presenting cells during the initiation of an
immune response. It has been shown that LFA-1 can trans-
mit multiple intracellular signals in different types of leuko-
cytes, including T cells (12, 13, 15–18). We and others have
shown before that upon activation of LFA-1 and subsequent
ligand engagement dramatic changes in T cell morphology
take place that are associated with alterations in the organi-
zation of the actin cytoskeleton (13, 17). As the GTPase Rac-1
is a key regulatory molecule for actin cytoskeletal organiza-
tion, we decided to study whether LFA-1 was able to induce
activation of this GTPase in T cells. Herein we show that
LFA-1 induces a potent and transient activation of Rac-1.
Maximal Rac-1 activity is reached 10 min after the induction
of LFA-1 activation and then declines to basal levels at longer
times. This transient stimulation of Rac-1 activity was ob-
served using three different methods for activation of LFA-1:
(i) addition of Mn2, (ii) clustering the LFA-1 molecules, and
(iii) direct stimulation with activating mAbs. The transient
Rac-1 stimulation suggests that distinct signals are regulat-
ing this small GTPase. When we analyzed the signaling
molecules that could account for this transient behavior of
Rac-1 activity, we found that Vav and PI3K/Akt-1 play an
important role. Furthermore, by using constitutively active
FIG. 4. LFA-1 induces activation of Akt-1 in T cells. A, time course of LFA-1-stimulated Akt-1 activity. T lymphoblasts were plated onto
ICAM-1-coated dishes, stimulated with 200 M MnCl2 for several time periods, lysed, and subjected to Western blotting. Active Akt-1 was detected
with anti-phospho-Akt-1 (upper panels). Total levels of Akt-1 were analyzed with anti-Akt-1 antibody (lower panels). The -fold increase in Akt-1
activity is also quantified. B, T cells were pretreated for 30 min with either the PI3K inhibitor LY294002 (100 M) or with the anti-LFA-1 mAb LIA
3/2.1 (10 g/ml) to prevent the interaction between LFA-1 and ICAM-1 (not shown). Cells were stimulated for the indicated times with 200 M
MnCl2, and active and total Akt-1 was determined as in A.
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and dominant-negative mutants of these molecules and phar-
macological inhibitors, we provide evidence that Vav and
PI3K/Akt-1 play opposing roles on the regulation of the ac-
tivity of Rac-1, controlling the activation and inactivation
phases of Rac-1 activity, respectively. In line with previous
observations (37) in other lymphocyte systems, our findings
also indicate that in the context of LFA-1 signaling, Vav
activation is independent of the PI3K activity, because inhi-
bition of this enzyme does not affect the activity of this GEF
(Fig. 2). Our experimental data are integrated in the model
presented in Fig. 8, which is based on the following points.
First, the observed time courses of the LFA-1-mediated
changes in the activity of Vav and PI3K/Akt-1 are consistent
with the postulated activating/inhibitory effects exerted on
Rac-1 by Vav and Akt-1, respectively (see Figs. 1–5). Second,
overexpression of constitutively active and dominant-nega-
tive forms of Vav induce activation and abrogation of LFA-1-
mediated Rac-1 activation, respectively (Fig. 2). Third, inhi-
bition of PI3K did not affect Vav activation (Fig. 2). Fourth,
transfection with a constitutively active form of Akt-1
blunted Rac-1 activity, and overexpression of dominant-neg-
ative Akt-1 mutant induced activation of Rac-1 (Fig. 6). Fifth,
pre-treatment of the cells with the PI3K inhibitors LY294002
or wortmannin prevented the decline in the activity of Rac-1
(Fig. 5).
In contrast to Vav, which, because of its GEF activity, in-
duces Rac activation, the mechanism whereby PI3K/Akt inhib-
its Rac is presently unclear. Because phosphorylation by Akt
usually leads to inhibition of the substrate function, we ana-
lyzed the possibility that the observed inhibition of the Rac-1
activity might be a result of Akt-mediated Rac-1 phosphoryla-
tion. Rac-1 and other members of the small G protein family,
including Cdc42 and RhoA, possess a Ser residue preceded by
arginines that resemble the consensus sequence for Akt sub-
strates (RLRPLSY). However, according to the algorithm de-
veloped by Yaffe et al. (52), this sequence is unlikely to be
actually phosphorylated by Akt in vivo, because it has a worse
score (0.3192) when compared with well established substrates
such as BAD (0.1775), GSK3 (0.1697), FOXO3a (0.1174), or
eNOS (0.2032). Moreover, the crystal structure of Rac-1, de-
scribed by Hirshberg et al. (53), further indicates that this Ser
is not exposed on the surface of this small GTPase, therefore
making difficult its accessibility to Akt-1. In agreement with
these predictions, we could not detect a difference in the pat-
tern of Rac-1 phosphorylation in cells transfected with consti-
tutively active Akt-1 or treated with the PI3K inhibitor
LY294002 (Fig. 6). Our data are in contrast with a previous
study (51) that reported the direct phosphorylation of Rac-1 by
Akt. The discrepancy with our results might be explained in
part by the fact that this previous study was performed using
Akt in in vitro kinase assays with Rac-1-derived fluorescent
peptides as substrates. If direct phosphorylation/inhibition by
Akt-1 does not seem to be the key event, then other mecha-
nisms must be invoked to account for the observed LFA-1-de-
pendent inhibition of Rac-1 activity. One such alternative
mechanism involving the participation of a Rac-1-GTPase-ac-
FIG. 5. LFA-1 modulates Rac-1 activity through PI3K. The kinetics of Rac-1 activation mediated by LFA-1 was compared in HSB-2 T cells
untreated or pretreated with 100 M PI3K inhibitor LY294002 for 30 min. LFA-1 was then induced to signal by inducing clustering of the integrin
for the indicated times with the anti LFA-1 mAb LIA3/2.1 (see “Materials and Methods”). The active Rac-1 fraction from lysates (GTP-Rac-1; upper
panel) was pulled down with GST-PAK-CRIB, fractionated by SDS-PAGE, and immunoblotted using anti-Rac-1 antibody. Total Rac-1 (Rac-1; lower
panel) was analyzed in fractions of total lysates reserved for loading controls and detected by Western blotting with anti-Rac-1 antibody. The -fold
activation increased was quantified, and the Rac-1 kinetics is represented on the right of the panels. The kinetics of Akt-1 activation in this
experiment, obtained as in Fig. 4A using anti-Akt-1-phospho-Ser polyclonal antibody (Akt-1; upper left panel), and the anti-total Akt-1 antibody
(Akt-1; lower left panel) are also included. The inhibition of the PI3K/Akt-1 signaling in T cells pretreated with LY294002 (100 M) is shown in Akt-1
right panels. The Akt-1 -fold activation was quantified and graphically represented on the right of the Akt-1 panels.
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tivating protein has been published very recently (54). Further
studies will be required to elucidate this possibility in the
context of LFA-1 signaling in T cells.
We have also observed that maintaining the activity of Rac
at high levels, by overexpressing constitutively active forms
of Rac or Vav or by pharmacologically inhibiting PI3K/Akt,
blocked the LFA-1-dependent changes in morphology and the
motility of T cells. It has been observed before that the effects
of active Rac on cell morphology and motility depend on the
cellular system analyzed, with examples where active Rac
either stimulates or inhibits cell motility (31, 55, 56). How
could active Rac lead to the blockade of T cell motility and
morphology? We speculate that constitutively active Rac
might exert its effects by disruption of the fine temporal
regulation of the organization of the actin cytoskeleton. Rac
possesses several downstream effectors (26, 28), including
the phosphatidylinositol phosphate 5-kinase, an enzyme that
catalyzes the conversion of phosphatidylinositol 4-phosphate
to phosphatidylinositol 4,5-bisphosphate, and the serine/
threonine kinase PAK, a well established Rac effector that
regulates several downstream components. Together, both
enzymes regulate important cytoskeletal processes. The
product of phosphatidylinositol phosphate 5-kinase, phos-
phatidylinositol 4,5-bisphosphate, has an important role in
the regulation of the cytoskeleton and the interaction be-
tween the cytoskeleton and the membrane (57). On the other
hand, PAK may regulate several cytoskeletal proteins (e.g.
filamin) or regulators of the cytoskeleton, like cofilin (58, 59).
In particular, cofilin participates in the cycle or severing of
actin fibers that are subsequently polymerized by Arp2/3 and
formins (60, 61). This process of actin depolymerization/
polymerization is cyclical. It could be possible that by main-
taining Rac in an activated state the cyclical changes that
lead to variations in cell morphology and motility are altered.
FIG. 6. Akt-1 inactivates Rac-1. A,
the T cell line HSB-2 was transfected with
EGFP-vector cDNA, DN-Akt-1, and CA-
Akt-1. After 24 h of electroporation, cells
were washed twice in RPMI medium and
lysed as explained under “Materials and
Methods.” The active Rac-1 fraction from
total lysates (GTP-Rac-1; upper panel)
was pulled down with GST-PAK-CRIB,
fractionated by SDS-PAGE, and immuno-
blotted using an anti-Rac-1 antibody. To-
tal Rac-1 (Rac-1; lower panel) was ana-
lyzed in fractions of total lysates reserved
for loading controls and detected by West-
ern blotting (WB) with anti-Rac-1. The
quantification of active Rac-1, referred to
as control pEGFP-transfected cells, is
represented in the graph below the pan-
els. B, HSB-2 T cells transfected with
tagged Rac-AU5 cDNA pretreated () or
not () with the PI3K inhibitor LY294002
at 100 M and cells co-transfected with
CA-Akt-1 and tagged Rac-AU5 cDNAs
were starved for 2 h. After this period,
LFA-1 activation was induced by cross-
linking (XL-Lia3/2.1). All the cells were
lysed in Buffer E, and cleared lysates
were incubated with anti-AU5 mAb to
precipitate tagged Rac-AU5. Immunopre-
cipitates (IP) were fractionated by SDS-
PAGE and immunoblotted with an anti-
body that specifically recognizes the
consensus sequence (RLRPLpS/pT) phos-
phorylated by Akt-1. The total Rac-AU5
and total Rac was detected in the last two
panels.
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FIG. 7. Role of PI3K/Akt and Rac-1 signaling in adhesion, polarization, migration, and activation of PYK-2 in T cells. A, transfection of
constitutively active Rac-1 and Vav blocks LFA-1-dependent cell polarization. HSB-2 T cells were transiently transfected with CA-Vav cDNA and
CA-Rac-1. After 16–24 h, cells were starved for 90 min in 20 mM Hepes-RPMI 1640 medium and, after this period, plated onto ICAM-1-coated dishes
and LFA-1 stimulated with the mAb KIM-127 anti-CD18 and recorded by time-lapse videomicroscopy; the frames shown correspond to a time point of
90 min after the contact between cells and ligand ICAM-1. The phase contrast (left) and fluorescence (right) images showing transfected cells are shown.
B, inhibition of PI3K blocks LFA-1-dependent cell polarization. T lymphoblasts were either pretreated for 30 min with the PI3K inhibitor LY294002
(100 M) or not pretreated before allowing them to adhere on poly-L-lysine or ICAM-1-coated plastic wells for 60 min at 37 °C. LFA-1 activation was
induced with either Mn2 (200 M) or anti-CD18 stimulatory mAb KIM-127 (10 g/ml). Non-adherent T lymphoblasts were washed, and adherent cells
were fixed, permeabilized, stained, and photographed. C, LFA-1-induced activation of tyrosine kinase PYK-2 is blocked by PI3K inhibition. T
lymphoblasts were either pretreated for 30 min with the PI3K inhibitor LY294002 (100 M) or not treated before plating them on ICAM-1-coated plastic
dishes for 40 min at 37 °C. LFA-1 activation was induced with either Mn2 (200 M) or anti-CD18 stimulatory mAb KIM-127 (10 g/ml). After this
period, all T cells in the dishes were lysed, PYK-2 was immunoprecipitated with specific antibodies, and in vitro autophosphorylation kinase activity
was measured. Parallel control samples were run to show equal loading by Western blot (WB).
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Activated Rac, acting through PAK, by “freezing” cofilin in a
phosphorylated/inactive conformation, may unbalance the
process leading to changes in morphology and cell motility.
Therefore it could be possible that Rac activity must be
temporally regulated in the cycle of activation and inactiva-
tion, and disruption of this process may lead to dramatic
effects on morphology and motility. Taken together, our re-
sults demonstrate an important role for Vav and PI3K/Akt-1
in the LFA-1 signaling pathway that temporally controls in T
cells the activity of Rac-1 and changes in cell morphology and
motility.
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molecules the integrin LFA-1 exerts a spatio-temporal control on cytoskeletal organization, morphological changes, and motility of T cells.
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